>…because the FDA may treat these old/new patents as late listed ones.<
The new law presumably covers this scenario. However, I haven’t read it in detail and don’t intend to.
My interest in MRX is on the cosmetic side rather than the derm side. I don’t especially care what happens with the Solodyn patent, although it is instructive to watch how it unfolds.
Market Data 
Markets 
AI
